Gabexate

Gabexate
Gabexate.svg
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Gabexate is a synthetic protease inhibitor used primarily in the treatment of acute pancreatitis and disseminated intravascular coagulation (DIC). It functions by inhibiting the activity of proteases, which are enzymes that break down proteins, thereby reducing inflammation and other symptoms associated with these conditions.

Mechanism of Action

Gabexate works by inhibiting the activity of several serine proteases, including trypsin, kallikrein, and plasmin. By blocking these enzymes, gabexate reduces the inflammatory response and prevents the degradation of proteins that can lead to tissue damage.

Clinical Uses

Gabexate is primarily used in the management of:

• Acute Pancreatitis: Gabexate is administered to reduce the inflammatory response and prevent further pancreatic damage.
• Disseminated Intravascular Coagulation (DIC): It helps in managing the coagulation abnormalities by inhibiting the proteases involved in the coagulation cascade.

Administration

Gabexate is typically administered intravenously due to its rapid metabolism and short half-life. The dosage and duration of treatment depend on the severity of the condition being treated.

Side Effects

Common side effects of gabexate include:

• Hypotension
• Nausea
• Allergic reactions

Pharmacokinetics

Gabexate is rapidly metabolized in the body, with a short half-life of approximately 1 to 2 minutes. It is hydrolyzed by plasma esterases into inactive metabolites, which are then excreted in the urine.

Related pages

• Protease inhibitor
• Acute pancreatitis
• Disseminated intravascular coagulation

• 
  Gabexate